Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 18/20 | 0.53 |
| ▸ | RPS6KA2 | Q15349 | 5/20 | 0.46 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.46 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762599 | 0.84 | RPS6KA3 (0.56) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL19252841 | 0.84 | RPS6KA3 (0.53) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1982725 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL30137600 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1982846 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1981787 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5760326 | 0.80 | RPS6KA3 (0.54) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL30137612 | 0.78 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL30137580 | 0.78 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL4038902 | 0.77 | RPS6KA2 (0.52) | RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620950-A | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109071542-B | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2019-05-09 | — | — | US | disclosed |
| EP-3416964-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | Phoenix Molecular Designs (CA) | 2018-12-26 | — | — | EP | disclosed |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2018-09-25 | — | — | US | disclosed |
| WO-2017141116-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | WO | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1641796-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| EP-1472255-B1 | AZA-ARYLPIPERAZINES | HOFFMANN LA ROCHE (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | RPS6KA3 4/4885RPS6KA2 2/4885RPS6KA1 3/4885 |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | RPS6KA2, RPS6KA5, RPS6KA1 | RPS6KA3 6/4885RPS6KA2 1/4885RPS6KA1 3/4885 |
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | RPS6KA3 3909/4885RPS6KA2 3947/4885RPS6KA1 2882/4885 |
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | RPS6KA3 1773/4885RPS6KA2 1443/4885RPS6KA1 1818/4885 |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | RPS6KA3 4/4885RPS6KA2 2/4885RPS6KA1 3/4885 |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | RPS6KA3 4/4885RPS6KA2 1/4885RPS6KA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.